Goat anti-Mouse IgG (H+L) Secondary Antibody [HRP]

• Reactivity: Mu
• Applications: WB, ELISA, IHC
• Clonality: Polyclonal
• Host: Goat
• Conjugate: HRP
• Concentration: LYOPH

Goat anti-Mouse IgG (H+L) Secondary Antibody [HRP] Summary

• Description: Purity > 95% based on SDS-PAGE. Goat serum was obtained from healthy animals of US origin and under the care of a registered veterinarian. After reconstituted, prepare fresh working dilution daily.
  
  Store lyophilized material at 2-8C. For long term storage after reconstitution, dilute with 50% glycerol and store at -20C as a liquid.
• Immunogen: This Goat anti-Mouse IgG (H+L) Secondary Antibody [HRP] was developed against purified mouse IgG (H&L).
• Specificity: Based on IEP, this Goat anti-Mouse IgG (H+L) Secondary Antibody [HRP] reacts with heavy gamma chains on mouse IgG and light chains on all mouse immunoglobulins.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity: Affinity purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:200-1:5000
  • Immunohistochemistry 1:500-1:5000
  • Immunohistochemistry-Paraffin
  • Western Blot 1:200-1:5000
• Application Notes: This conjugate is suitable for all immunoassay applications.

Reactivity Notes

Based on IEP, no reactivity is observed to non-immunoglobulin mouse serum immunoglobulins

Packaging, Storage & Formulations

• Storage: Store lyophilized antibody at 4C. Mix reconstituted liquid with an equal volume of glycerol, aliquot contents and freeze at -20C or below for long term storage.
• Buffer: 10 mM Sodium Phosphate, 0.15 M Sodium Chloride, pH 7.2, 1 % (w/v) BSA, Protease/IgG free
• Preservative: 0.1% Kathon
• Concentration: LYOPH
• Purity: Affinity purified
• Reconstitution Instructions: Rehydrate with 1.1 ml of deionized water and let stand 30 minutes at room temperature to dissolve. (Product has been overfilled to ensure complete recovery.) Centrifuge to remove any particulates. Prepare fresh working dilution daily.

Background

Antibodies, also known as immunoglobulins (Igs) are critical for immunity and are grouped into five primary classes: IgG, IgM, IgA, IgD, and IgE. The most abundant antibody isotype is immunoglobulin G (IgG) with concentrations ranging from 7.5-22 mg/ml in human serum and has a molecular weight of 150 kDa. The major effector functions of IgG include neutralization, opsonization, complement fixation and antibody dependent cell-mediated cytotoxicity (ADCC). This monomeric immunoglobulin, expressed on the surface of mature B cells, is often depicted as a Y-shape and comprised of 2 heavy chains and 2 light chains linked by disulfide bonds. The heavy chain is type gamma including subtypes gamma 1, gamma 2, gamma 3, and gamma 4 while the light chain is either a kappa or lambda chain. An IgG molecule has two antigen binding sites, each consisting of a heavy and light chain N-terminal variable domain. When combined with the constant heavy chain 1 (Ch1) and the constant light chain domains, it forms the fragment antigen-binding (Fab) region (2 per antibody). The remaining domains (Ch2-Ch4) of both heavy chains make up the Fc region and contain a site for covalently linking an enzymatic or fluorochrome probe, such as HRP or Janelia Fluor 549, for target detection and visualization (1,2,3).

The 4 IgG subclasses, sharing 95% amino acid identity, include IgG1, IgG2, IgG3, and IgG4 for humans and IgG1, IgG2a, IgG2b, and IgG3 for mice. The relative abundance of each human subclass is 60% for IgG1, 32% for IgG2, 4% for IgG3, and 4% for IgG4. In an IgG deficiency, there may be a shortage of one or more subclasses (4).

References

1. Painter RH. (1998) Encyclopedia of Immunology (Second Edition). Elsevier. 1208-1211

2. Chapter 9 - Antibodies. (2012) Immunology for Pharmacy. Mosby 70-78

3. Schroeder H, Cavacini, L. (2010) Structure and Function of Immunoglobulins. J Allergy Clin Immunol. 125(2 0 2): S41-S52. PMID: 20176268

4. Vidarsson G, Dekkers G, Rispens T. (2014) IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 5:520. PMID: 25368619

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Secondary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IgG (H+L) Antibody (NBP1-75130)(8)

Publications using NBP1-75130

• Rashu, R;Ninkov, M;Wardell, CM;Benoit, JM;Wang, NI;Meilleur, CE;D'Agostino, MR;Zhang, A;Feng, E;Saeedian, N;Bell, GI;Vahedi, F;Hess, DA;Barr, SD;Troyer, RM;Kang, CY;Ashkar, AA;Miller, MS;Haeryfar, SMM; Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens PLoS pathogens 2023-06-29 [PMID: 37384813] (ELISA)
• Christopher M. Bourne, Patrick Wallisch, Megan M. Dacek, Thomas J. Gardner, Stephanie Pierre, Kristen Vogt, Broderick C. Corless, Mamadou A. Bah, Jesus E. Romero-Pichardo, Angel Charles, Keifer G. Kurtz, Derek S. Tan, David A. Scheinberg Host Interactions with Engineered T-cell Micropharmacies Cancer Immunology Research 2023-09-01 [PMID: 37379366] (Immunocytochemistry/ Immunofluorescence)
• Horspool AM, Sen-Kilic E, Malkowski AC et al. Development of an anti-Pseudomonas aeruginosa therapeutic monoclonal antibody WVDC-5244 Frontiers in cellular and infection microbiology 2023-04-14 [PMID: 37124031] (ELISA)
• Blackwood CB, Mateu-BorrAs M, Sen-Kilic E Et al. Bordetella pertussis whole cell immunization protects against Pseudomonas aeruginosa infections NPJ Vaccines 2022-11-10 [PMID: 36357402] (WB, Mouse)
  
  Details:
  Citation using the HRP version of this antibody.
• Barbier M, Lee KS, Vikharankar MS et al. Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2 Frontiers in Immunology 2022-08-15 [PMID: 36091051] (Immunocytochemistry/ Immunofluorescence)
• Lee KS, Russ BP, Wong TY Et al. Obesity and metabolic dysfunction drive sex-associated differential disease profiles in hACE2-mice challenged with SARS-CoV-2 iScience 2022-09-07 [PMID: 36068847] (ELISA)
  
  Details:
  Citation using the HRP version of this antibody.
• Wong TY, Lee KS, Russ BP Et al. Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge NPJ Vaccines 2022-03-15 [PMID: 35288576] (ELISA)
  
  Details:
  Citation using the HRP version of this antibody.
• Bosnakovski D, Ener ET, Cooper MS Et al. Inactivation of the CIC-DUX4 oncogene through P300/CBP inhibition, a therapeutic approach for CIC-DUX4 sarcoma Oncogenesis 2021-10-13 [PMID: 34642317] (ICC/IF)
  
  Details:
  Citation using the HRP version of this antibody.